
- /
- Supported exchanges
- / US
- / TRVI.NASDAQ
Trevi Therapeutics Inc (TRVI NASDAQ) stock market data APIs
Trevi Therapeutics Inc Financial Data Overview
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Trevi Therapeutics Inc data using free add-ons & libraries
Get Trevi Therapeutics Inc Fundamental Data
Trevi Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -50 939 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Trevi Therapeutics Inc News

Catalyst Watch: Amazon Prime Day, Delta earnings and stock-by-stock trade deal implications
[Business and stock exchange data on the screen.] Torsten Asmus Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the ev...


TRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. (NASDAQ: TRVI) and Encourages Long-Term Investors to Contact the Firm
PHILADELPHIA, June 26, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Trevi Therapeutics, Inc. (NASDAQ: TRVI) (“Trevi”) on behalf of the company’s long-term invest...

Trevi Therapeutics Prices $100 Mln Public Offering Of Common Stock
(RTTNews) - Trevi Therapeutics, Inc. (TRVI), a clinical-stage biopharmaceutical company focused on developing Haduvio - oral nalbuphine ER for chronic cough in idiopathic pulmonary fibrosis - IPF and ...

Trevi Therapeutics prices $100M stock at $5.75 per share
* Clinical-stage biopharmaceutical company Trevi Therapeutics (NASDAQ:TRVI [https://seekingalpha.com/symbol/TRVI]) priced [https://seekingalpha.com/pr/20125587-trevi-therapeutics-announces-pric...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.